Difference between revisions of "Template:Major side effects of bicalutamide alone"
Jump to navigation
Jump to search
| Line 27: | Line 27: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
| + | [[Category:Medication templates]] | ||
[[Category:Templates that generate named references]] | [[Category:Templates that generate named references]] | ||
</noinclude> | </noinclude> | ||
Revision as of 02:56, 11 November 2018
| Frequency | Class | Side effect |
|---|---|---|
| Very common (≥10%) |
Reproductive system and breast disorders |
• Breast tendernessa • Gynecomastiaa |
| Common (≥1% and <10%) |
General and psychiatric disorders |
• Asthenia • Decreased libido • Erectile dysfunction • Hot flashes |
| Skin and subcutaneous tissue disorders |
• Decreased body hair | |
| Hepato-biliary disorders | • Elevated liver enzymesb | |
| Uncommon (≥0.1% and <1%) |
Immune system disorders | • Hypersensitivity reactions, including angioedema and hives |
| Rare (<0.1%) and unknown |
Respiratory, thoracic, and mediastinal disorders |
• Interstitial lung diseasec |
| Skin and subcutaneous tissue disorders |
• Sensitivity to light | |
| Hepato-biliary disorders | • Liver toxicityd | |
Footnotes and sources
a = Incidence of breast changes of up to 80 to 90%. Mild-to-moderate in 90% of cases. Incidence greatly decreased in combination with castration. b = Elevated liver enzymes rarely severe and usually transient, resolving or improving with continued therapy or with discontinuation. Incidence of 3.4% relative to 1.9% for placebo in a high-dose (150 mg/day) 4,000-patient trial. c = Six case reports of interstitial lung disease published (as of 2016). Incidence of 0.01% (12 patients) in an 87,000-patient cohort. d = Five case reports of hepatotoxicity published (as of 2016). No cases in a high-dose (150 mg/day) 4,000-patient trial (incidence of <0.03%). Sources: [1][2][3][4][5][6][7] | ||
References
- ↑ Mcleod DG (September 2002). "Emerging role of adjuvant hormonal therapy". Urology. 60 (3 Suppl 1): 13–20, discussion 21. doi:10.1016/S0090-4295(02)01562-5. PMID 12231039.
- ↑ https://pdf.hres.ca/dpd_pm/00009096.PDF
- ↑ Bennett CL, Raisch DW, Sartor O (October 2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". Annals of Internal Medicine. 137 (7): 625. doi:10.7326/0003-4819-137-7-200210010-00029. PMID 12353966.
An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.
- ↑ Molina Mancero, Guillermo; Picón, Xavier; Di Tullio, Fernando; Ernst, Glenda; Dezanzo, Pablo; Salvado, Alejandro; Chertcoff, Julio F (2016). "Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado" [Fatal interstitial lung disease associated with maximum androgen blockade. Report of one case]. Revista médica de Chile. 144 (10): 1356–1359. doi:10.4067/S0034-98872016001000017. ISSN 0034-9887.
- ↑ Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C (May 2016). "Drug-induced photosensitivity to bicalutamide - case report and review of the literature". Photodermatol Photoimmunol Photomed. 32 (3): 161–4. doi:10.1111/phpp.12230. PMID 26663090.
- ↑ Yun GY, Kim SH, Kim SW, Joo JS, Kim JS, Lee ES, Lee BS, Kang SH, Moon HS, Sung JK, Lee HY, Kim KH (April 2016). "Atypical onset of bicalutamide-induced liver injury". World J. Gastroenterol. 22 (15): 4062–5. doi:10.3748/wjg.v22.i15.4062. PMC 4823258. PMID 27099451.
- ↑ Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU Int. 91 (5): 455–61. doi:10.1046/j.1464-410X.2003.04026.x. PMID 12603397.